Genmab A/S
CSE:GMAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Genmab A/S
CSE:GMAB
|
DK |
|
C
|
Citius Oncology Inc
NASDAQ:CTOR
|
US |
|
C
|
Colgate-Palmolive Co
LSE:0P59
|
US |
|
W
|
Wilmar International Ltd
OTC:WLMIF
|
SG |
|
A
|
Alexander's Inc
SWB:AXE
|
US |
|
Healthcare Realty Trust Inc
NYSE:HR
|
US |
|
H
|
Halma PLC
F:H11
|
UK |
|
C
|
Clearmind Medicine Inc
NASDAQ:CMND
|
CA |
|
General Inc
TSE:6755
|
JP |
|
G
|
Garmin Ltd
NYSE:GRMN
|
CH |
|
N
|
NetApp Inc
XHAM:NTA
|
US |
|
T
|
Thor Industries Inc
F:TIV
|
US |
|
E
|
Emerita Resources Corp
F:LLJA
|
CA |
|
C
|
Crocs Inc
F:C7N
|
US |
|
Yankuang Energy Group Co Ltd
OTC:YZCHF
|
CN |
|
Monro Inc
NASDAQ:MNRO
|
US |
|
H
|
Highwood Asset Management Ltd
XTSX:HAM
|
CA |
Bankruptcy Probability
Genmab A/S's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Genmab A/S Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| DK |
|
Genmab A/S
CSE:GMAB
|
142.4B DKK |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
AbbVie Inc
NYSE:ABBV
|
470.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
226.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences, Inc
NASDAQ:GILD
|
188.9B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
133.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Moderna Inc
NASDAQ:MRNA
|
78.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.3B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
53.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Natera Inc
NASDAQ:NTRA
|
59.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
43.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Genmab A/S's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Genmab A/S has total debt of 5B USD. This includes both short-term (0 USD) and long-term (5B USD) debt.
You can find a full breakdown on its Balance Sheet.